"Phase 2 data reported at 2021 AD/PD Conference showed gamma frequency neuromodulation was safe and well tolerated
Over the 6-month period, patients in the treatment group exhibited a significant 84% slowing of functional decline in ADCS-ADL scores as well as a significant 83% slowing in memory and cognitive decline as measured by MMSE scores compared to placebo/sham
Patients in the treatment group demonstrated a significant 61% reduction in whole brain atrophy and volumetric loss associated with AD, compared to placebo/sham at 6 months, demonstrating disease modification potential..."
Lire la suite
Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease
BUSINESS WIRE, 16/03/2021
Partagé par :
Beesens TEAM

Informations liées
Thématiques
Thérapies digitales
Alzheimer
Accueil Neurologie
Structures
HAS
GOOGLE
Poppins et la dyslexie : une thérapie numérique
YOUTUBE,
Partagé par : MERYEME CHIBOUB
The Current State Of FDA-Approved AI-Enabled Medical Devices
MEDICAL FUTURIST,
Partagé par : Beesens TEAM
EkiYou : une thérapie digitale pour optimiser la gestion du diabète
BUZZ-ESANTE,
Partagé par : Beesens TEAM
DTx : Histoire d'un "insuccès" en France, Deprexis
BASILSTRATEGIES,
Partagé par : Beesens TEAM
Membres Premium A la une
Coach professionnelle certifiée / Formatrice
Fondatrice - KoKrea conseil
Human & IT - Collaboratif & réalité virtuelle
Associée KOS AVOCATS en e-santé